Aviva’s Phathom Pharmaceuticals PHAT Stock Holding History

Aviva’s Portfolio PHAT Stock Details PHAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-29,463	Closed	-$1.11M	–	952
2021 Q1	$1.11M	Buy	+29,463	New	+$1.23M	0.01%	894

Other funds holding PHAT

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

MVM

Medicxi Ventures Management St. Helier, Jersey $982M AUM 210.17% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Aviva's PHAT Position: Q2 2021 in Review

Aviva sold out of Phathom Pharmaceuticals (PHAT) in Q2 2021, closing a stake of 29,463 shares — an estimated $1.11M sold.

Aviva first reported a position in PHAT in Q1 2021 and held it in 1 quarter. The position peaked at $1.11M in Q1 2021. 79 funds tracked by Wall St. Rank hold PHAT as of Q2 2021.

Aviva reported no remaining Phathom Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
Aviva sold 29,463 Phathom Pharmaceuticals shares in Q2 2021, an estimated $1.11M.
Aviva first reported a position in Phathom Pharmaceuticals in Q1 2021 and held it in 1 quarter.
Aviva's Phathom Pharmaceuticals position peaked at $1.11M in Q1 2021.
79 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2021.

Based on Aviva's 13F filing for Q2 2021, filed 10 Aug 2021.